Mounjaro® (Tirzepatide) - Doctor-Led Weight & Metabolic Treatment
Check your eligibility online. Prescription issued only if medically appropriate.
See Variations
Why Choose a Regulated Medical Pathway?
Fast Online Assessment
Secure medical questionnaire completed in minutes.
Clinician Review
Prescription issued only after licensed physician approval.
Regulated Pharmacy
Medication dispensed through EU/UK licensed pharmacies.
Ongoing Support
Clinical guidance available during treatment.
Medically Reviewed & Clinically Supervised
All treatment decisions are made by licensed clinicians. Mounjaro is supplied only following individual medical assessment.
How It Works: Mounjaro via Transtoyou
Safe, doctor-led pathway, from secure assessment to regulated delivery.
-
STEP 1 - Complete Secure Medical Assessment
Start by completing a brief online medical questionnaire. You’ll provide your health history, current medications, and treatment goals. This helps our clinicians understand your medical profile safely and efficiently.
-
STEP 2 - Clinician Review & Eligibility
A licensed Transtoyou physician reviews your information. They assess your suitability for Mounjaro based on clinical criteria, contraindications, and your health goals. You receive a decision and recommendations, typically within 24 hours.
-
STEP 3 - Prescription Issued If Medically Appropriate
If the clinician determines Mounjaro is suitable for you, a legitimate prescription is issued. If not, you receive a medical explanation and may be guided toward alternatives.
-
STEP 4 - Regulated Pharmacy Dispensing
Your prescription is filled by a licensed EU/UK pharmacy. The dispensing process is fully compliant with local pharmacy regulations. Only regulated pharmacies handle your medication.
-
STEP 5 - Discreet Delivery to Your Door
Your medication is shipped discreetly and securely to your address. Packaging is plain and professional, protecting your privacy while meeting all legal standards.
-
STEP 6 - Ongoing Support & Follow-Up
Available follow-up support helps you manage side effects, answer questions, and adjust your plan as needed. Clinical support continues throughout your treatment journey.
Select your option
1 pen — 2.5 mg
The medically recommended starting dose. Designed to help your body adapt to tirzepatide while minimising early side effects before therapeutic escalation begins.
1 pen — 5 mg
The first full therapeutic dose. Introduced after the initiation phase to begin delivering measurable metabolic and appetite-regulating effects.
1 pen — 7.5 mg
An intermediate escalation step for enhanced metabolic response. Prescribed when additional appetite control or glycaemic improvement is clinically appropriate.
1 pen — 10 mg
A higher therapeutic dose supporting continued weight and glucose management. Used based on individual progress and tolerability.
1 pen — 12.5 mg
Advanced dose adjustment for patients requiring stronger metabolic support. Escalation is guided strictly by clinical assessment..
1 pen — 15 mg
The maximum approved maintenance dose. Prescribed when clinically indicated and well tolerated for sustained therapeutic effect.
Starter pack: Mounjaro 2 Pens (1 x 2,5 mg and 1 x 5 mg)
Includes both the initiation and first therapeutic dose. Designed for a structured and seamless treatment start under medical supervision.t.
What Is Mounjaro®?
Mounjaro® is a prescription-only injectable medication containing tirzepatide. It is used in the treatment of Type 2 diabetes and, where approved, chronic weight management under medical supervision.
Mounjaro is administered once weekly and works by targeting two key metabolic hormone pathways involved in appetite regulation and glucose control.
Unlike traditional GLP-1 treatments, Mounjaro activates both GLP-1 and GIP receptors, resulting in a broader metabolic effect that influences:
- Appetite and satiety
- Insulin response
- Blood glucose regulation
This dual mechanism is what clinically differentiates Mounjaro from earlier GLP-1 therapies.
How Mounjaro Works in the Body
| Hormone Pathway | Activated By Mounjaro | Clinical Effect |
|---|---|---|
| GLP-1 receptor | Yes | Reduced appetite, slower gastric emptying |
| GIP receptor | Yes | Improved insulin sensitivity and glucose uptake |
| Dual metabolic signaling | Yes | Enhanced blood sugar control and satiety |
Why Dual-Hormone Therapy Matters
Most earlier treatments target only a single metabolic pathway. By activating both GLP-1 and GIP, tirzepatide supports multiple aspects of metabolic regulation at the same time.
This includes improved appetite control, more stable glucose levels after meals, and enhanced insulin efficiency. Clinical studies show this dual activation is associated with greater average metabolic improvements compared to single-pathway GLP-1 therapie
Medical Uses of Mounjaro
| Indication | Medical Purpose | Prescription Required |
|---|---|---|
| Type 2 diabetes | Improve glycaemic control | Yes |
| Chronic weight management (for adults with BMI ≥30, or ≥27 with weight-related conditions, where approved) | Appetite and intake reduction | Yes |
| Metabolic dysfunction | Improve insulin response | Yes |
Prescription-Only and Medically Supervised
Mounjaro directly affects hormonal and metabolic systems. For this reason, it is classified as a prescription-only medicine.
Medical supervision is required to:
- Assess eligibility and contraindications
- Determine appropriate dose escalation
- Monitor side effects and tolerability
- Adjust treatment where necessary
Mounjaro is never supplied without clinician approval.
Mounjaro Dosage & Treatment Approach
Treatment with Mounjaro follows a structured dose escalation protocol. Gradual increases help reduce gastrointestinal side effects and improve long-term tolerability.
Not all patients require higher doses. The appropriate maintenance dose is determined individually by the prescribing clinician.
Mounjaro Weekly Dose Escalation Schedule
| Phase | Dose | Minimum Duration | Clinical Purpose |
|---|---|---|---|
| Initiation | 2,5 mg | 4 weeks | Tolerance assessment (not full therapeutic dose) |
| Step 1 | 5 mg | ≥4 weeks | Initial therapeutic effect |
| Step 2 | 7,5 mg | ≥4 weeks (if required) | Additional metabolic response |
| Step 3 | 10 mg | ≥4 weeks (if required) | Enhanced glycaemic & weight effect |
| Step 4 | 12,5 mg | ≥4 weeks (if required) | Further dose adjustment |
| Maintenance | 15 mg | Ongoing | Maximum approved maintenance dose |
Typical Clinical Response Timeline
| Timeframe | Possible Effects | Notes |
|---|---|---|
| Weeks 1–2 | Early glucose response | Appetite changes may begin |
| Weeks 4–8 | Improved metabolic stability | Dose escalation may occur |
| Weeks 8–12 | Measurable weight reduction | Continued supervision required |
| 3+ months | Sustained response | Dose individualised |
Clinical Trial Outcomes (Tirzepatide)
| Outcome | Outcome | Observed Effect (Clinical Trials) |
|---|---|---|
| HbA1c reduction | Significant reduction vs baseline | Observed in adults with Type 2 diabetes |
| Body weight change | Clinically meaningful weight reduction | Dose-dependent effect |
| Weekly administration | Once-weekly injection | Improved adherence compared to daily dosing |
Safety & Side Effects
The most commonly reported side effects of Mounjaro are gastrointestinal and may include nausea, diarrhoea, constipation, reduced appetite, vomiting, and abdominal discomfort.
These effects are typically mild to moderate and are most noticeable during dose escalation. They often improve as the body adapts to treatment.
Serious adverse events are uncommon but may include pancreatitis or gallbladder disease. Patients should seek medical attention if they experience severe abdominal pain or persistent symptoms.
Mounjaro carries a warning regarding the potential risk of thyroid C-cell tumours and should not be used in individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2).
Safety Overview
| Outcome | Outcome | Observed Effect (Clinical Trials) |
|---|---|---|
| HbA1c reduction | Significant reduction vs baseline | Observed in adults with Type 2 diabetes |
| Body weight change | Clinically meaningful weight reduction | Dose-dependent effect |
| Weekly administration | Once-weekly injection | Improved adherence compared to daily dosing |
Who May Not Be Suitable for Mounjaro
Who May Not Be Suitable for Mounjaro
Mounjaro should not be used in individuals with:
- A personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
- Known hypersensitivity to tirzepatide
Caution is required in patients with:
- A history of pancreatitis
- Severe gastrointestinal disease
- Renal or hepatic impairment
- Pregnancy or breastfeeding
Eligibility is determined through clinician review in accordance with regulatory guidance.
Mounjaro vs Traditional GLP-1 Treatments
| Category | Examples | Clinical Action |
|---|---|---|
| Common effects | Nausea, digestive symptoms | Usually transient |
| Less common risks | Gallbladder issues | Monitoring required |
| Rare serious risks | Pancreatitis | Immediate medical attention |
Medical Supervision Is Essential
Mounjaro is a prescription-only medicine. Treatment decisions, dose escalation, and continuation are based on ongoing clinical evaluation.
Medication is supplied only when clinically appropriate.
Frequently Asked Questions about Mounjaro®
Clinical data shows that blood glucose levels may begin to improve within 1–2 weeks after starting tirzepatide.
Appetite reduction is commonly reported within 2–4 weeks, particularly during the initial dose escalation phase.
Clinically measurable weight reduction typically becomes apparent after 8–12 weeks, with continued weight loss observed over several months when treatment is maintained under medical supervision.
Individual response varies depending on dosage, metabolism, and adherence.
In clinical studies, patients treated with tirzepatide experienced average weight reductions of approximately 15–22% of body weight over extended treatment periods.
Actual results depend on:
- Dose level
- Treatment duration
- Individual metabolic profile
- Lifestyle factorsWeight loss outcomes vary and cannot be guaranteed.
Tirzepatide is approved in Europe for the treatment of Type 2 diabetes.
Approval and reimbursement for chronic weight management may vary by country and indication.
A licensed physician determines whether treatment is appropriate based on local regulations and medical guidelines.
No. Mounjaro is a prescription-only medicine.
Any supplier offering Mounjaro without a medical assessment or prescription is operating outside regulatory frameworks. Safe use requires physician evaluation and monitoring.
Yes, when the process is doctor-led and pharmacy-dispensed.
Safe online prescribing includes:
- Medical questionnaire review
- Licensed physician approval
- Dispensing by a regulated EU or UK pharmacy
- Ongoing medical oversight
This model is compliant with EU and UK healthcare regulations.
Treatment typically starts at 2,5 mg once weekly for tolerance assessment.
The dose is then gradually increased to 5 mg, and potentially up to 7,5–15 mg, depending on individual response and tolerability.
Dose adjustments are always determined by the prescribing physician.
The most frequently reported side effects are gastrointestinal and include:
- Nausea
- Diarrhea
- Constipation
- Reduced appetite
These effects are usually mild to moderate and often decrease as the body adjusts to treatment.
Serious adverse effects are uncommon but may include:
- Pancreatitis
- Gallbladder disease
Mounjaro is not suitable for patients with certain thyroid conditions or specific endocrine disorders. Full screening is required before prescribing.
Mounjaro may be used long-term under medical supervision, provided the treatment remains effective and well tolerated.
Treatment duration is reassessed regularly by the prescribing physician based on clinical response and safety.
If a dose is missed and less than 4 days have passed, it may be taken as soon as remembered.
If more than 4 days have passed, the missed dose should be skipped and the regular schedule resumed.
In some cases, yes. However, medication combinations require careful adjustment to avoid adverse effects, particularly hypoglycaemia.
All combination therapy decisions must be made by a healthcare professional.
If you are not eligible, the physician will explain why and may suggest alternative treatment options where appropriate.
No medication is supplied without clear medical justification.
References & Scientific Sources
- European Medicines Agency (EMA) - Mounjaro EPAR
- U.S. Food and Drug Administration (FDA) - Mounjaro Prescribing Information
- New England Journal of Medicine - Tirzepatide versus Semaglutide Once Weekly
- New England Journal of Medicine - Once-Weekly Tirzepatide for the Treatment of Obesity
- American Diabetes Association - Tirzepatide and Dual GIP/GLP-1 Receptor Agonists
